middle.news
NeuroScientific Reports 80% Clinical Response in Crohn’s Disease Patients
10:02am on Tuesday 28th of July, 2026 AEST
•
Biotechnology
Read Story
NeuroScientific Reports 80% Clinical Response in Crohn’s Disease Patients
10:02am on Tuesday 28th of July, 2026 AEST
Key Points
80% clinical response in Special Access patients
Two Phase 2 trials planned for Crohn’s disease
Manufacturing technology transfer to Q-Gen enters validation
Cash position of $4.6 million supports development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuroscientific Biopharmaceuticals (ASX:NSB)
OPEN ARTICLE